BOARD OF DIRECTORS
Dominique Cheneval, Ph.D.
Dr. Cheneval has close to thirty years experience in the pharmaceutical
industry. He has held positions with the pharmaceutical giants Sandoz and
Novartis, where he led teams in cutting edge research both in numerous drug
discovery programs and compound profiling.
In addition to his research and pre-clinical development activities, he has received training in pharmaceutical development, leadership and business management.
Dr. Cheneval graduated with a Ph.D. in Biochemistry from the Swiss Federal Institute of Technology (ETH, Zürich) and was a Postdoctoral Research
Fellow at The Johns Hopkins University School of Medicine (Baltimore, Maryland).
Tania Kastelic, Ph.D.
Dr. Kastelic has more than twenty-five years of pharmaceutical industry experience including positions as Postdoctoral Fellow and Research Associate with
Sandoz and Novartis Pharma AG (Switzerland). She was involved in several drug discovery projects in the field of inflammation and rheumatoid arthritis.
Dr. Kastelic discovered Novation's novel and unique mRNA modulation technology. She brings to Novation superior research skills, proven by her recognition
of the potential of modulating mRNA stability as a therapeutic target of orally active drugs.
Dr. Kastelic has a Ph.D. from the Biochemistry, Cellular and Molecular Biology Program of The Johns Hopkins University School of Medicine (Baltimore, Maryland)
and a Master of Science in Chemistry from Simon Fraser University (Burnaby, B.C.).
Gordon J. Politeski
Mr. Politeski is an experienced industry executive who was the founding President and CEO of Biomira Inc., a cancer diagnostics and therapeutics company.
During his tenure at Biomira, Mr. Politeski took the Company from its initial financing to the TSE and subsequently to the NASDAQ.
Mr. Politeski has held a number of senior management positions including President and General Manager of Allergan Pharmaceuticals, Director of the
Pharmaceutical Group, Pharmacia, and CEO of Ondine Medical Laser Group. A graduate of the University of Saskatchewan and the Amos Tuck Executive
Program at Dartmouth College (Hanover, NH), Mr. Politeski has been active in supporting startup biotechnology companies with management, strategy and
Kjell Stenberg, Ph.D.
Dr. Kjell Stenberg held senior R&D and position development management
positions with AstraZeneca. He brought several new candidate drugs into the
company in infectious diseases, oncology and neurology. Since 2001,
Stenberg has also founded and managed nine biotech companies and two
investment funds in Sweden, Denmark and North America. He has managed
companies with drug candidates from early preclinical stage, up to and
including global phase 3 trials. In 2009, Dr. Stenberg and BioMS Medical
Corp were awarded "License Deal of the Year" by Scrips for the license deal
with Eli Lilly, USA for the use of dirucotide for secondary-progressive
Dr. Stenberg has patents on a novel drug delivery
formulation that are the foundation for two Nasdaq-listed biotech
companies in Sweden. Dr. Stenberg has his scientific background from
the Karolinska Institute in Stockholm and has published extensively in
the fields of virology, oncology and cell toxicology.
Ms. Tejani, MBA, is an experienced venture capitalist and company builder.
She has been involved in commercialization of technology and venture capital
since 1990 as founder of Smart Seed Fund, a seed stage technology fund focused
on hands on management assistance and financing for technology startups.
Ms. Tejani currently works in development finance with donors, governments and
NGOs to enhance the capacity of Microfinance and SME banks through training
academies and in climate finance to reduce greenhouse emissions by developing
Green Lending programs. She has executed development projects in over 25
countries in Africa, the Middle East and Central Asia.